Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 1

Status

Withdrawn 2Completed 1

Sponsor Class

OTHER_GOV 6OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Rectal Neoplasms 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

Cyclophosphamide 2042Radiotherapy 1859Cisplatin 1825Carboplatin 1533Gemcitabine 1434Paclitaxel 1289Bevacizumab 1270Docetaxel 1202pembrolizumab 1199Oxaliplatin 1160Capecitabine 1144Fluorouracil 1061Dexamethasone 971Rituximab 919Nivolumab 908Magnetic Resonance Spectroscopy 862Etoposide 839Doxorubicin 823Drug Therapy 792Radiosurgery 776Irinotecan 775Cytarabine 736fludarabine 716Leucovorin 676Lenalidomide 608fludarabine phosphate 564Temozolomide 552Radiation 541Filgrastim 540Cetuximab 537

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × Interventional × Hydralazine × Clear all
NCT00996060 2016-01-18

Use of Hydralazine and Valproic Acid in Advanced Solid Tumor Malignancies

New Mexico Cancer Research Alliance

Phase 1 Completed
29 enrolled
Thoracic

Lung Neoplasms

NCT00575640 2015-03-04

Hydralazine as a Demethylating Agent in Rectal Cancer

University of Arkansas

Phase 1/2 Withdrawn
Gastrointestinal

Rectal Neoplasms

NCT00575978 2015-03-04

Hydralazine as Demethylating Agent in Breast Cancer

University of Arkansas

Phase 1/2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡